Urogen Pharma (NASDAQ:URGN) Given Average Rating of “Moderate Buy” by Brokerages

Urogen Pharma (NASDAQ:URGN) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $52.3750.

Several research analysts have issued reports on URGN shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $56.00 price target on shares of Urogen Pharma in a report on Thursday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. TD Cowen boosted their target price on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Oppenheimer boosted their target price on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Finally, Guggenheim upped their target price on Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 6th.

Insider Transactions at Urogen Pharma

In other news, General Counsel Jason Smith sold 1,519 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the sale, the general counsel owned 53,141 shares in the company, valued at $2,260,618.14. The trade was a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Schoenberg sold 871 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total transaction of $37,383.32. Following the completion of the transaction, the insider directly owned 59,882 shares of the company’s stock, valued at $2,570,135.44. This represents a 1.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 73,067 shares of company stock valued at $3,356,854 over the last ninety days. Insiders own 4.80% of the company’s stock.

Institutional Trading of Urogen Pharma

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Urogen Pharma during the second quarter valued at $117,814,000. Jefferies Financial Group Inc. purchased a new stake in Urogen Pharma in the 2nd quarter worth about $80,947,000. SG Americas Securities LLC lifted its stake in Urogen Pharma by 20.3% in the 1st quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock worth $29,808,000 after acquiring an additional 280,199 shares in the last quarter. Opaleye Management Inc. boosted its position in Urogen Pharma by 0.7% during the 2nd quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock worth $52,992,000 after acquiring an additional 9,996 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Urogen Pharma in the 4th quarter valued at about $26,350,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Trading Down 2.6%

NASDAQ:URGN opened at $41.63 on Thursday. The company has a 50-day moving average of $43.97 and a 200-day moving average of $32.88. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -21.03 and a beta of 1.57. Urogen Pharma has a twelve month low of $15.86 and a twelve month high of $50.81.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. On average, research analysts forecast that Urogen Pharma will post -0.2 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company uses its proprietary RTGel reverse-thermal hydrogel technology to provide sustained delivery of medicines directly to affected tissues.

UroGen’s primary commercial product is JELMYTO (mitomycin), a gel-based formulation approved in the United States for the treatment of adults with low-grade upper tract urothelial cancer. The company’s pipeline has also included UGN-102, an investigational formulation of mitomycin being developed for patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer.

Founded in 2004, UroGen is headquartered in Princeton, New Jersey, and primarily serves the U.S.